troglitazone has been researched along with Experimental Hepatoma in 3 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, M | 1 |
| Saekusa, Y | 1 |
| Dewa, Y | 1 |
| Nishimura, J | 1 |
| Matsumoto, S | 1 |
| Shibutani, M | 1 |
| Hasumi, K | 1 |
| Mitsumori, K | 1 |
| Guo, YT | 1 |
| Leng, XS | 1 |
| Zhao, JM | 1 |
| Lin, XH | 1 |
| Li, T | 1 |
| Zhu, JY | 1 |
| Yu, J | 1 |
| Qiao, L | 1 |
| Zimmermann, L | 1 |
| Ebert, MP | 1 |
| Zhang, H | 1 |
| Lin, W | 1 |
| Röcken, C | 1 |
| Malfertheiner, P | 1 |
| Farrell, GC | 1 |
3 other studies available for troglitazone and Experimental Hepatoma
| Article | Year |
|---|---|
Hepatocarcinogenic susceptibility of rasH2 mice to troglitazone in a two-stage hepatocarcinogenesis model.
Topics: Animals; Biomarkers, Tumor; Body Weight; Carcinogens; Chromans; Disease Models, Animal; Disease Susc | 2009 |
[Pexoxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats].
Topics: Animals; Antineoplastic Agents; Chromans; Diethylnitrosamine; Ligands; Liver Neoplasms, Experimental | 2005 |
Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Chromans; Cyclin-Dependent Kin | 2006 |